GLP-1 Therapies - Market Insights, Competitive Landscape, and Market Forecast - 2034

GLP-1 Therapies Market Summary

Overview

• The GLP-1 Therapies market is estimated at USD 62.83 billion in 2025 and is projected to reach USD 254.19 billion by 2034. Growth is anchored in the rapid expansion of obesity and chronic weight-management use, the commercial success of tirzepatide- and semaglutide-based therapies, and the arrival of oral GLP-1 formulations.
• The global GLP-1 Therapies market is growing at a CAGR of 16.8% during the forecast period from 2026 to 2034.
• By molecule type, the biologics segment dominated the GLP-1 Therapies market with a 74% share in 2025.
• By drug class, the GLP-1 receptor agonists segment dominated the GLP-1 Therapies market with a 57% share in 2025.
• By active ingredient, the semaglutide segment dominated the GLP-1 Therapies market with a 43% share in 2025.
• By route of administration, the subcutaneous injections segment dominated the GLP-1 Therapies market with an 82% share in 2025.
• By therapeutic application, the Type 2 Diabetes segment dominated the GLP-1 Therapies market with a 51% share in 2025.
• North America dominated the global GLP-1 Therapies market revenue with a 58% share in 2025, representing the highest regional market share globally.

GLP-1 therapies are a class of incretin-based medicines that mimic the action of the naturally occurring glucagon-like peptide-1 hormone, stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite. Originally developed for type 2 diabetes, GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists have become the standard of care in chronic weight management and are advancing rapidly into cardiovascular risk reduction, obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis, and other cardiometabolic and neurodegenerative indications. The market is organized by molecule type across biologics and small molecules; by drug class across GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists; by active ingredient, including semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, tirzepatide, and orforglipron; by route of administration across subcutaneous injections and oral formulations; and by therapeutic application, led by type 2 diabetes and obesity/chronic weight management, with cardiovascular risk reduction and obstructive sleep apnea emerging as fast-growing labeled indications. Driven by blockbuster commercial performance, an expanding late-stage pipeline of next-generation single, dual, and triple agonists, accelerating regulatory approvals, and the recent arrival of once-daily oral pills, GLP-1 therapies have become one of the fastest-growing and most closely watched categories in global pharmaceuticals.

GLP-1 Therapies Market Key Growth Drivers

• The rising global burden of obesity and type 2 diabetes is expanding demand for incretin-based therapy, with the World Health Organization and World Obesity Federation both reporting continued increases in adult obesity prevalence across developed and emerging markets.
• The arrival of once-daily oral GLP-1 pills is broadening access, with Novo Nordisk launching the Wegovy pill in the United States in January 2026 as the first oral GLP-1 approved for weight management, followed by Eli Lilly's FDA approval of Foundayo (orforglipron) in April 2026 as the first small-molecule GLP-1 pill for obesity.
• A deep late-stage pipeline of next-generation single, dual, and triple agonists, including retatrutide and survodutide, is expanding the addressable market, with industry trackers estimating roughly 190 obesity-focused drug candidates in active development as of 2026.
• Accelerating regulatory approvals and label expansions, including Wegovy's cardiovascular risk reduction and MASH indications and Zepbound's obstructive sleep apnea indication, are broadening the addressable patient population and reinforcing recurring demand.
• Heavy investment in manufacturing capacity is easing supply constraints, including Eli Lilly's build-up of a roughly USD 1.5 billion pre-launch inventory of orforglipron and Novo Nordisk's expanded fill-finish capacity in North Carolina supporting the Wegovy pill launch.
• Surging dealmaking and licensing activity is accelerating pipeline breadth, including AstraZeneca's up-to-USD-18.5-billion obesity and diabetes alliance with China's CSPC Pharmaceutical in January 2026 and Regeneron's up-to-USD-2-billion licensing agreement for Hansoh Pharma's dual GIP/GLP-1 candidate HS-20094.
• The convergence of blockbuster commercial momentum, oral-formulation access expansion, pipeline depth, and label broadening is expected to sustain strong double-digit growth in the GLP-1 Therapies market through 2034.

Key Companies in GLP-1 Therapies Market

The competitive landscape is led by the following active manufacturers:

• Novo Nordisk
• Eli Lilly and Company
• AstraZeneca
• Sanofi
• Amylin Pharmaceuticals
• GlaxoSmithKline (GSK)
• Alvogen
• Jiangsu Hansoh Pharmaceutical Group
• Shanghai Benemae Pharmaceutical
• Hangzhou Jiuyuan Gene Engineering

Factors Contributing to the Growth of the GLP-1 Therapies Market

Market Drivers

Blockbuster Commercial Performance of Incretin-Based Therapies

Blockbuster commercial performance of incretin-based therapies is significantly boosting the GLP-1-based therapies market by demonstrating strong patient demand, expanding physician adoption, and encouraging pharmaceutical companies to invest in new GLP-1 and next-generation incretin therapies. In 2025, Novo Nordisk reported DKK 152.2 billion in total GLP-1 sales, while Eli Lilly's Mounjaro and Zepbound generated $36.5 billion combined, with sales growing 99% and 175%, respectively. These blockbuster revenues are increasing commercial confidence, accelerating geographic expansion, supporting investment in oral and next-generation formulations, and attracting competitors into the market, thereby expanding the overall GLP-1-based therapies market.

Rising Global Burden of Obesity and Type 2 Diabetes

The escalating global prevalence of obesity and type 2 diabetes is expanding the addressable patient population for GLP-1 therapies. The World Health Organization and World Obesity Federation continue to report rising adult obesity prevalence across North America, Europe, and increasingly in Asia-Pacific and Latin America, while the global type 2 diabetes population continues to grow in parallel with aging populations and changing lifestyles. GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists deliver substantial, durable weight reduction alongside glycemic control and cardiometabolic benefit, positioning them as first-line and increasingly preferred therapy. As disease prevalence rises and clinical guidelines increasingly recommend early GLP-1 use, demand for these therapies expands directly across the forecast period.

Market Restraints

Despite exceptional momentum, the GLP-1 Therapies market faces material constraints. High treatment cost and uneven insurance and government reimbursement, particularly outside the United States and Europe, restrict broad-based access and concentrate use among higher-income patients and geographies. Persistence and adherence remain limiting factors, with industry data indicating that roughly 28% of GLP-1 users discontinue treatment within one year, driven by gastrointestinal tolerability issues, injection burden, and cost. Manufacturing and supply-chain constraints associated with complex peptide synthesis have caused periodic shortages since 2022, prompting regulatory scrutiny of compounded and counterfeit GLP-1 products that pose safety risks and complicate branded-market forecasting. Looming patent expiries on early-generation active ingredients, including exenatide and liraglutide, and the approaching 2026 patent cliff for semaglutide in certain markets, are opening the door to biosimilar and generic competition, particularly from China and India, which could pressure branded pricing. Reimbursement policy uncertainty, the logistical complexity of cold-chain distribution for injectable formulations, and a still-developing long-term safety and cardiometabolic outcomes evidence base for newer dual and triple agonists further temper the pace of adoption, even as the underlying drivers of obesity prevalence, pipeline depth, and oral-formulation access expansion remain firmly intact.

GLP-1 Therapies Market Segment Analysis

The GLP-1 therapies market by molecule type (biologics, small molecules), drug class (GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists), active ingredients (semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, tirzepatide, orforglipron), route of administration (subcutaneous injections, oral), therapeutic application (type 2 diabetes, obesity/chronic weight management, cardiovascular risk reduction, obstructive sleep apnea), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Molecule Type

Dominant Subsegment: Biologics.

The biologics segment accounted for 74% of the GLP-1 Therapies market in 2025. Biologics dominate because nearly every currently marketed GLP-1 active ingredient, including semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, and tirzepatide, is a synthetic peptide manufactured through complex biologic production processes, and these agents account for the overwhelming majority of prescription volume and revenue across diabetes and obesity indications. The scale, injection-based delivery, and manufacturing complexity of these peptide therapies have long defined the category. However, small molecules are the fastest-growing molecule type following Eli Lilly's April 2026 approval of Foundayo (orforglipron), the first small-molecule GLP-1 receptor agonist, which offers simpler chemical synthesis, potentially lower manufacturing cost, and easier oral formulation than peptide-based biologics. As additional oral small-molecule candidates progress through late-stage development, this segment is expected to narrow the gap with biologics, though the depth of the approved biologics portfolio secures its leadership across the forecast period.

By Drug Class

Dominant Subsegment: GLP-1 Receptor Agonists.

The GLP-1 receptor agonists segment accounted for 57% of the GLP-1 Therapies market in 2025. GLP-1 receptor agonists lead the market because they encompass the broadest and most established portfolio of approved active ingredients, including semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, and orforglipron, spanning the longest history of clinical use, the widest set of approved indications, and the deepest global regulatory footprint across diabetes, obesity, and cardiovascular risk reduction. Dual GIP/GLP-1 receptor agonists, represented commercially by tirzepatide, are the fastest-growing drug class, propelled by superior average weight-loss outcomes relative to single-agonist therapies and the outsized commercial performance of Mounjaro and Zepbound, which together generated more than USD 60 billion in 2025 sales. As additional dual and triple agonists such as retatrutide advance toward approval, this segment is expected to continue gaining share, even as the breadth of the approved GLP-1 receptor agonist portfolio secures its leadership across the forecast period.

GLP-1 Therapies Market Region Analysis

Dominant Region: North America

North America accounted for 58% of the global GLP-1 Therapies market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects the presence of the two market-leading innovators, Novo Nordisk and Eli Lilly, both of which maintain their largest commercial infrastructure and highest list prices in the United States, alongside broad direct-to-consumer marketing, expanding employer and Medicare coverage, and the highest per-capita obesity and type 2 diabetes prevalence among developed markets. The United States hosts the earliest and broadest launches of new GLP-1 products, including the January 2026 Wegovy pill launch and the April 2026 Foundayo approval, and benefits from expanding Medicare Part D coverage for obesity medications beginning in April 2026. Heavy manufacturing investment, including expanded North Carolina fill-finish capacity and multibillion-dollar pre-launch inventory build-up, reinforces the region's supply leadership. Strong clinical-trial infrastructure, FDA regulatory clarity including the Commissioner's National Priority Voucher program, and deep payer familiarity with the drug class anchor North America's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the GLP-1 Therapies market. The region's elevated CAGR is driven by rising obesity and type 2 diabetes prevalence, rapid healthcare-infrastructure investment, and an accelerating wave of domestic drug development across China, Japan, India, South Korea, and Australia. China is emerging as both a major consumption market and a global GLP-1 innovation hub, with companies including Jiangsu Hansoh Pharmaceutical Group licensing dual GIP/GLP-1 and oral GLP-1 candidates to Regeneron and Merck, and Shanghai Benemae Pharmaceutical and Hangzhou Jiuyuan Gene Engineering advancing beinaglutide and biosimilar semaglutide products ahead of anticipated 2026 patent expiries. India is scaling low-cost generic and biosimilar production capacity to widen affordable access across South Asia. Government healthcare investment, an expanding diagnosed patient population, and growing domestic manufacturing capability are accelerating regional adoption and positioning Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 58% of the global GLP-1 Therapies market revenue in 2025. The United States dominates on the strength of Novo Nordisk's and Eli Lilly's commercial leadership, broad and expanding payer coverage, the earliest global launches of new oral and injectable formulations, and heavy investment in domestic manufacturing capacity, while Canada and Mexico contribute a smaller but growing share supported by expanding regulatory approvals and rising diagnosed obesity and diabetes prevalence.

Europe

Europe is a large and advanced regional market, supported by established European Medicines Agency regulatory pathways, strong clinical-research infrastructure across Germany, the United Kingdom, France, Italy, and Spain, and growing but uneven national reimbursement policies for obesity indications. Germany and the United Kingdom lead regional adoption, while broader European access to weight-management indications continues to expand as national health systems evaluate long-term cost-effectiveness evidence.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising obesity and diabetes prevalence, rapid healthcare-infrastructure investment, and an accelerating wave of domestic drug development across China, Japan, India, South Korea, and Australia. China's growing base of GLP-1 licensing deals and biosimilar development, Japan's steady adoption of innovator therapies, and India's low-cost generic manufacturing capacity are accelerating regional volume growth and clinical-trial activity.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Rising obesity prevalence, including in markets such as Brazil, expanding private-pay and telehealth access channels, and gradual efforts to broaden public reimbursement for metabolic disease are widening access, while international licensing partnerships and growing local manufacturing interest support the build-out of regional supply.

GLP-1 Therapies Market Competitive Landscape

The GLP-1 Therapies market is classified as Concentrated. Two integrated innovators with global commercial scale, Novo Nordisk and Eli Lilly and Company, together account for the substantial majority of branded revenue and anchor the top tier, while established pharmaceutical companies including AstraZeneca, Sanofi, and GlaxoSmithKline (GSK) compete through licensed pipeline assets and legacy incretin franchises, and specialized generic, biosimilar, and Chinese domestic manufacturers, including Amylin Pharmaceuticals, Alvogen, Jiangsu Hansoh Pharmaceutical Group, Shanghai Benemae Pharmaceutical, and Hangzhou Jiuyuan Gene Engineering, compete on cost, regional access, and next-generation licensing partnerships, increasing competition as early-generation active ingredients approach patent expiry.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Concentrated, with Novo Nordisk and Eli Lilly leading and a fast-growing field of licensed-pipeline and generic/biosimilar challengers.
• Leading players: Novo Nordisk and Eli Lilly and Company anchor the top tier through blockbuster commercial franchises spanning injectable and oral GLP-1 products.
• Geographic reach: Leaders operate global commercial networks spanning North America, Europe, and Asia-Pacific; Novo Nordisk and Eli Lilly both maintain manufacturing and launch infrastructure across multiple continents.
• Pipeline breadth: Top players and licensing partners span single, dual, and triple agonist mechanisms, oral small-molecule programs, and combination therapies targeting obesity, diabetes, and adjacent cardiometabolic conditions.
• Formulation innovation: Ownership of both injectable and oral GLP-1 platforms, including the first-to-market oral pills launched in 2026, is a decisive commercial advantage.
• Strategic partnerships: Licensing tie-ups with Chinese biotechs, such as AstraZeneca's alliance with CSPC Pharmaceutical, Regeneron's agreement with Hansoh Pharma, and Merck's license for Hansoh's oral GLP-1 candidate, extend pipeline reach.
• M&A and licensing activity: Active dealmaking, including AstraZeneca's up-to-USD-18.5-billion CSPC alliance and multibillion-dollar licensing agreements for Chinese-originated GLP-1 candidates.
• Manufacturing capabilities: Large-scale peptide synthesis, fill-finish capacity, and multibillion-dollar pre-launch inventory build-up are key competitive moats for the leading innovators.
• Innovation focus: Dual and triple agonist scale-up, oral small-molecule development, and next-generation combination therapies targeting superior efficacy and dosing convenience.

GLP-1 Therapies Market Recent Developmental Activities

In April 2026, Eli Lilly and Company received FDA approval for Foundayo (orforglipron), the first small-molecule GLP-1 pill for chronic weight management, offering once-daily dosing without food or water restrictions. Strategic significance: Establishes Lilly's second blockbuster obesity franchise and the first approved oral small-molecule GLP-1 therapy.

In January 2026, Novo Nordisk launched the Wegovy pill (oral semaglutide 25 mg) in the United States, the first oral GLP-1 approved for chronic weight management and cardiovascular risk reduction, supported by expanded North Carolina manufacturing capacity. Strategic significance: Extends the Wegovy franchise into needle-averse patient populations and defends Novo Nordisk's oral GLP-1 leadership.

GLP-1 Therapies Market Segmentation

GLP-1 Therapies Market by Molecule Type

• Biologics
• Small Molecules

GLP-1 Therapies Market by Drug Class

• GLP-1 Receptor Agonists
• Dual GIP/GLP-1 Receptor Agonists

GLP-1 Therapies Market by Active Ingredients

• Semaglutide
• Liraglutide
• Dulaglutide
• Exenatide
• Lixisenatide
• Tirzepatide
• Orforglipron

GLP-1 Therapies Market by Route of Administration

• Subcutaneous Injections
• Oral

GLP-1 Therapies Market by Therapeutic Application

• Type 2 Diabetes
• Obesity/Chronic Weight Management
• Cardiovascular Risk Reduction
• Obstructive Sleep Apnea

GLP-1 Therapies Market by Geography

• North America GLP-1 Therapies Market
• United States GLP-1 Therapies Market Size in USD million (2023-2034)
• Canada GLP-1 Therapies Market Size in USD million (2023-2034)
• Mexico GLP-1 Therapies Market Size in USD million (2023-2034)
• Europe GLP-1 Therapies Market
• Germany GLP-1 Therapies Market Size in USD million (2023-2034)
• United Kingdom GLP-1 Therapies Market Size in USD million (2023-2034)
• France GLP-1 Therapies Market Size in USD million (2023-2034)
• Italy GLP-1 Therapies Market Size in USD million (2023-2034)
• Spain GLP-1 Therapies Market Size in USD million (2023-2034)
• Rest of Europe GLP-1 Therapies Market Size in USD million (2023-2034)
• Asia-Pacific GLP-1 Therapies Market
• China GLP-1 Therapies Market Size in USD million (2023-2034)
• Japan GLP-1 Therapies Market Size in USD million (2023-2034)
• India GLP-1 Therapies Market Size in USD million (2023-2034)
• Australia GLP-1 Therapies Market Size in USD million (2023-2034)
• South Korea GLP-1 Therapies Market Size in USD million (2023-2034)
• Rest of Asia-Pacific GLP-1 Therapies Market Size in USD million (2023-2034)
• Rest of the World (RoW) GLP-1 Therapies Market
• Middle East GLP-1 Therapies Market Size in USD million (2023-2034)
• Africa GLP-1 Therapies Market Size in USD million (2023-2034)
• South America GLP-1 Therapies Market Size in USD million (2023-2034)

Key Takeaways from the GLP-1 Therapies Market Report Study

• Market size analysis for the current GLP-1 Therapies market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global GLP-1 Therapies market.
• Various opportunities available for competitors in the GLP-1 Therapies market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current GLP-1 Therapies market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for GLP-1 Therapies market growth in the future?

Target audience who can benefit from this GLP-1 Therapies market report study

• GLP-1 Therapies product providers
• Research organizations and consulting companies
• Neurodegenerative disease therapeutics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in GLP-1 Therapies
• Various end-users who want to know more about the GLP-1 Therapies market and the latest technological developments in the GLP-1 Therapies market.

Frequently Asked Questions

Q1. What is the growth rate of the GLP-1 Therapies market?

The GLP-1 Therapies market is projected to expand at a CAGR of 16.8% during the forecast period from 2026-2034.

Q2. What is the market size of the GLP-1 Therapies market?

The GLP-1 Therapies market is estimated at USD 62.83 billion in 2025 and is projected to reach USD 254.19 billion by 2034.

Q3. Which region dominates the GLP-1 Therapies market?

North America dominated the GLP-1 Therapies market with a 58% share of global revenue in 2025, supported by the commercial leadership of Novo Nordisk and Eli Lilly, broad and expanding payer coverage, the earliest global launches of new oral and injectable formulations, and the highest per-capita obesity and diabetes prevalence among developed markets. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the GLP-1 Therapies market?

The principal drivers are the blockbuster commercial performance of tirzepatide- and semaglutide-based therapies, with Mounjaro reaching approximately USD 39.1 billion and Zepbound approximately USD 22.9 billion in 2025; the rising global burden of obesity and type 2 diabetes; the January 2026 and April 2026 launches of the first oral GLP-1 pills; a deep late-stage pipeline of next-generation dual and triple agonists; and accelerating regulatory label expansions into cardiovascular risk reduction and obstructive sleep apnea.

Q5. Who are the major players in the GLP-1 Therapies market?

The major players include Novo Nordisk, Eli Lilly and Company, AstraZeneca, Sanofi, Amylin Pharmaceuticals, GlaxoSmithKline (GSK), Alvogen, Jiangsu Hansoh Pharmaceutical Group, Shanghai Benemae Pharmaceutical, and Hangzhou Jiuyuan Gene Engineering, among other active providers profiled in the Competitive Landscape section. Novo Nordisk and Eli Lilly and Company lead through blockbuster commercial franchises spanning injectable and oral GLP-1 products.

This product will be delivered within 2 business days.